TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01862653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
Study: NCT02175914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
Study: NCT04110080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multimodal pain management
Description: Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: goal directed fluid management
Description: Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative carbohydrate loading
Description: Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor nephrectomy
Description: All patient will have laparoscopic nephrectomy procedure with transplant surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Donor nephrectomy
Description: All patient will have laparoscopic nephrectomy procedure with transplant surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: transabdominal plane and rectus sheath nerve block
Study: NCT03028935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo instructor-led exercise program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Undergo instructor-led nutritional education program
Study: NCT03821116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Swedish milk from cow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soured milk (filmjölk)
Description: Swedish soured milk (from cow milk).
Study: NCT02727452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Study: NCT02004457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABBT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TAU
Study: NCT02424682

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT03979924

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trismus rehabilitation
Description: The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,...) in order to strengthen the stretching.
Study: NCT02142569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRYR + TRF
Description: CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
Study: NCT05166031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV and nOPV2
Description: Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV and nOPV2
Description: Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV and nOPV2
Description: Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
Study: NCT00508118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: on bypass

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: on bypass
Study: NCT01834040

Intervention type: OTHER
Group type: OTHER
Intervention: Intralesional/ Intravenous of Autologous Stem cells.
Description: Intralesional/ Intravenous of Autologous MNCs per dose
Study: NCT03851315

Intervention type: DEVICE
Intervention: permanent left bundle branch area pacing
Description: Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
Study: NCT01845129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atDCS
Description: atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: atDCS
Description: atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
Study: NCT03721406

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: ropivacaine administerd via thoracic paraveretebral catheter
Study: NCT01279421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network HIV Testing
Description: Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Network Intervention
Description: Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
Study: NCT01513460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 50µg once daily
Description: NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18µg once daily
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flu/Sal
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu/Sal
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flu/Sal
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVA237 placebo + Tiotropium placebo.
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 placebo + Tiotropium placebo.
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237 placebo + Tiotropium placebo.
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Study: NCT00381810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be supplied as a liquid for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study: NCT00720291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
Study: NCT04077931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Walking on treadmill with fixed 0% grade inclination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Walking on treadmill with fixed 0% grade inclination
Study: NCT03537196

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400 mg and Daclatasvir 60 mg
Description: All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400 mg and Daclatasvir 90 mg
Description: For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
Study: NCT00720291

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
Study: NCT01192139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: Tablets, Oral, 5 mg, once daily, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin XR
Description: Tablets, Oral, 500 mg. once daily, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR (FDC tablet)
Description: Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR (FDC tablet)
Description: Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
Study: NCT02142569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol-enriched Fraction of Palm Oil (TRF)
Description: TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
Study: NCT00131404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
Study: NCT03579004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil is used in two cycles of neoadjuvant chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ivor Lewis esophagogastrectomy
Description: Open Ivor Lewis esophagogastrectomy
Study: NCT01305616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification with yellow-tinted intraocular lens
Description: Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Phacoemulsification with yellow-tinted intraocular lens
Description: Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
Study: NCT03048981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Blood samples before and after 10 day intake of maximum dose fish oil
Study: NCT05043896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Li-ESWT
Description: Li-ESWT twice weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5Mg Tab
Description: tadalafil 2.5mg once daily

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tadalafil 2.5Mg Tab
Description: tadalafil 2.5mg once daily
Study: NCT03977376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guide of hosting
Description: Guide of hosting with information about hospitalization to decrease anxiety
Study: NCT00219531

Intervention type: BEHAVIORAL
Intervention: perception of rectal balloon distention
Description: functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.

Intervention type: BEHAVIORAL
Intervention: perception of rectal balloon distention
Description: functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
Study: NCT00003824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalexin
Description: 500 mg oral bid for 3 days starting the night before resection
Study: NCT03537196

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir and Daclatasvir for 24 weeks
Description: In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
Study: NCT05113914

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test
Description: An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
Study: NCT03117413

Intervention type: OTHER
Group type: OTHER
Intervention: Positron emission tomography scan
Description: * Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)

Intervention type: OTHER
Group type: OTHER
Intervention: Positron emission tomography scan
Description: * Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)
Study: NCT04870918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care intervention
Description: Health education will be carried out by the nurse.
Study: NCT00764673

Intervention type: DEVICE
Group type: OTHER
Intervention: 3DKnee
Description: Subjects with knee osteoarthritis and willing to participate in the study
Study: NCT01014468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Intravitreal injection)
Description: Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Intravitreal injection)
Description: Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
Study: NCT00131404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo capsule once daily. 52 week treatment period.
Study: NCT00637663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study: NCT01644604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2211 Renal Denervation System
Description: A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
Study: NCT02741557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
Study: NCT02104570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping with tension

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio taping without tension

Intervention type: OTHER
Group type: OTHER
Intervention: Fatigue protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fatigue protocol
Study: NCT00448305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 + paclitaxel
Description: EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Description: EndoTAG-1 44 mg/m² twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m² weekly
Study: NCT02741557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV FDC
Description: DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV FDC
Description: DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
Study: NCT01973361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound debridement
Description: Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
Study: NCT00159224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir simplification strategy
Description: Simplification
Study: NCT01973361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best practice wound care
Description: Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
Study: NCT00546884

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MI condition
Description: Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
Study: NCT01758653

Intervention type: OTHER
Intervention: No study intervention
Description: There is no study-related intervention.
Study: NCT00159224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir simplification strategy
Description: Simplification
Study: NCT02540083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBT and FFDM
Description: Subjects underwent FFDM breast imaging followed by DBT breast imaging
Study: NCT00261443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium or Valproate with placebo (PBO)
Description: Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium or Valproate with Aripiprazole
Description: Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day
Study: NCT04259957

Intervention type: DEVICE
Intervention: Immersive Virtual Reality
Description: Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
Study: NCT01293240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
Study: NCT00546884

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GI
Description: The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.